Andra AP fonden Has $23.61 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Andra AP fonden raised its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 144,900 shares of the company's stock after purchasing an additional 1,800 shares during the quarter. Andra AP fonden's holdings in Zoetis were worth $23,609,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new position in Zoetis during the 3rd quarter valued at $31,000. First Personal Financial Services bought a new position in Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new position in Zoetis during the 3rd quarter valued at $33,000. Finally, Dunhill Financial LLC boosted its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after acquiring an additional 75 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Remove Ads

Zoetis Stock Up 1.8 %

Shares of NYSE:ZTS traded up $3.09 during midday trading on Friday, hitting $170.34. 3,296,788 shares of the stock were exchanged, compared to its average volume of 3,274,650. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The business's fifty day simple moving average is $166.72 and its two-hundred day simple moving average is $176.78. The company has a market capitalization of $76.28 billion, a PE ratio of 31.14, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. As a group, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis's dividend payout ratio is 36.56%.

Analyst Ratings Changes

Several research firms have recently weighed in on ZTS. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday. Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Morgan Stanley reduced their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Piper Sandler raised their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Finally, Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.